May 22 (Reuters) - The U.S. Food and Drug

Administration's (FDA) staff on Wednesday pointed to "notable

imbalance" in incidence of low blood sugar in patients with type

1 diabetes treated with Danish drugmaker Novo Nordisk's

long-acting weekly insulin.

A panel of independent FDA advisers will meet on Friday to

review and discuss the safety and effectiveness of Novo's

insulin, icodec - an under-the-skin injection.